TNFSF10 and neoplasm: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) has been considered as a promising agent for anti-tumor therapy for a long time, as cancer cells show higher sensitivity to TRAIL comparing to normal cells, highlighting TRAIL’s potential as a novel and effective anti-cancer drug.